Zinc chelation and Klf9 knockdown cooperatively promote axon regeneration after optic nerve injury

Ephraim F Trakhtenberg1, Yiqing Li1, Qian Feng1

  • 1Laboratories for Neuroscience Research in Neurosurgery, Boston Children's Hospital and Harvard Medical School, Boston, MA, United States; F.M. Kirby Neurobiology Center, Boston Children's Hospital and Harvard Medical School, Boston, MA, United States; Department of Neurosurgery, Boston Children's Hospital and Harvard Medical School, Boston, MA, United States.

Experimental Neurology
|November 7, 2017
PubMed

Insights

Combining zinc chelation (TPEN) with Klf9 gene knockdown significantly enhances axon regeneration after optic nerve injury. This approach promotes nerve repair and cell survival, offering therapeutic potential for central nervous system injuries.

Area of Science:

  • Neuroscience
  • Regenerative Medicine
  • Molecular Biology

Background:

  • Central nervous system (CNS) axon regeneration failure limits functional recovery after injury.
  • Existing pre-clinical strategies show limited success and potential risks.
  • Novel therapeutic approaches are needed to improve CNS repair.

Purpose of the Study:

  • To evaluate combinatorial treatments for promoting axon regeneration in a mouse optic nerve injury model.
  • To investigate the synergistic effects of TPEN (zinc chelator), Klf9 knockdown, oncomodulin, and cAMP analogs.
  • To assess treatment safety by avoiding manipulation of tumor suppressors or oncogenes.

Main Methods:

  • Traumatic optic nerve injury model in mice.
  • Treatment with TPEN (zinc chelator) and Klf9 short hairpin RNA (shRNA).
  • Combination therapy including oncomodulin and cAMP analog was also tested.

Main Results:

  • Co-treatment with TPEN and Klf9 knockdown demonstrated significantly enhanced axon regeneration compared to individual treatments.
  • This combination therapy also promoted substantial cell survival at later time points.
  • Other tested combinations showed only marginal improvements.

Conclusions:

  • Zinc (Zn2+) chelation combined with Klf9 suppression is a promising therapeutic strategy for optic nerve regeneration.
  • This approach may hold potential for treating a broader range of central nervous system injuries and diseases.
  • The combination therapy offers a potentially safer alternative by not targeting oncogenes or tumor suppressors.